Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK/PD of BI 705564 and Midazolam Interaction in Healthy Males
NCT03325712Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BI 705564 in IgE-mediated allergy and house dust mite allergy (8 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants With Drug-related Adverse Events up to 37 days. Started Nov 2017; status: completed.
02
Drugs
BI 705564
03
Conditions
IgE-mediated allergyhouse dust mite allergy
Beyond the preview
Go deeper on NCT03325712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03325712.